The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
NIH Director's New Innovator Award Program (DP2 - Clinical Trial Optional)
The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund.
- Application Due Date(s): August 21, 2020
- AIDS Application Due Date(s): August 21, 2020
RFA-RM-20-012 Expiration Date: August 22, 2020
Applicants must meet the definition of an Early Stage Investigator (ESI) at the time of submission application. An ESI is a new investigator (defined as a PD/PI who has not competed successfully for a significant NIH independent research award) who is within 10 years of completing his/her terminal research degree or end of post-graduate clinical training. See the Office of Extramural Research website for a complete list that do not disqualify a PD/PI as a new investigator and for frequently asked questions about the NIH Early Stage Investigator (ESI) Policy.
An extension to the 10-year period may be granted under certain circumstances (e.g., childbirth, family care responsibilities, clinical loan repayment requirements, disability or illness, natural or other disaster, etc.). An online vide tutorial is available for more information. It may take several weeks for the review process for the request, so applicants should plan accordingly. Note: If an applicant is not identified as an ESI in the eRA Commons, it may result in the application not being reviewed. Applicants are responsible for reviewing and/or updating their degree information in their eRA Commons account in a timely fashion.
Applicants must hold an independent research position at a domestic (U.S.) institution by September 1, 2021. For this FOA, an “independent research position” is a position that automatically confers eligibility to the investigator (based on institutional policy) to apply for R01 grants with appropriate institutional commitment of facilities for the conduct of the proposed research. Investigators still in training or mentored status (such as postdoctoral fellows) are not eligible to apply unless they have a written commitment from the institution stating they will be in an independent faculty position by September 1, 2021. The commitment is certified by the institution's submission of the application.
Applicants may submit or have an NIH R01 or other equivalent grant application pending concurrently with their NIH Director’s New Innovator Award application if it does not overlap substantially with their New Innovator Award application. However, if that pending grant becomes active prior to the NIH Director’s New Innovator Award, the applicant is no longer eligible to receive the New Innovator Award.
Awardees are required to commit at least three person-months (25%) of their research effort each year to activities supported by the New Innovator Award.
For more details regarding eligibility requirements, see FAQs on the New Innovator website.
There is no limit to the number of applications an institution may submit. Individuals may submit only one application as PD/PI in response to this FOA.
Awards are multi-year funded with all funds disbursed in the first year of the award. Awards will be up to $1,500,000 in direct costs (the equivalent of $300,000 in Direct Costs each year for five years) plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award.
Nicolas Buchler, PhD
Departments of Biology and Physics
Project Title: Rewiring The Yeast Brain: Redundancy And Interference In Genetic Networks
Charles Gersbach, PhD
Pratt School of Engineering
Project Title: Engineering Morphogenetic Factors For Enhanced Genetic Reprogramming
David Tobin, PhD
Molecular Genetics and Microbiology
Project Title: Modulating Eicosanoids To Treat Tuberculosis: Personalized, Host-Directed Therapy
Seok-Yong Lee, PhD
Department of Biochemistry
Project Title: Pharmacology and Biophysics of the Voltage-Gated Sodium Channel Nav 1.7
Duke University School of Medicine
Discovering New Regulators of CFTR and Fluid Secretion in Zebrafish
Chay T Kuo, PHd
Discovering Pathways Regulating Neurogenesis and Brain Remodeling After Injury